The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4420-4426

  Gifford, Gillian ^a   Paul, Jim ^a   Vasey, Paul A ^a   Kaye, Stanley B ^b   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; MICROSATELLITE DNA; PACLITAXEL; PROTEIN MLH1; TAXOID;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; FEMALE; GYNECOLOGIC CANCER; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ALLELES; CARBOPLATIN; CARRIER PROTEINS; CPG ISLANDS; DISEASE PROGRESSION; DNA; DNA METHYLATION; FEMALE; GENE SILENCING; HUMANS; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; RANDOM ALLOCATION; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042774430     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0732     Document Type: Article

References (33)

1. Wei SH, Brown R, Huang TH. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci 2003;983:243-50.
2. Strathdee G, MacKean M, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
3. Johnson PJ, Lo YMD. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002;48:1186-93.
4. Chang HW, Lee SM, Goodman SN, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (Bethesda) 2002;94:1697-703.
5. Thipgen JT. Chemotherapy of advanced ovarian cancer. Semin Oncol 2000;7:11-6.
6. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
7. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59: 67-70.
8. Hickey KP, Boyle KE, Jepps HM, et al. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 1999;80:1803-6.
9. Toyota M, Kopecky KJ, Toyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood 2001;97:2823-9.
10. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002;62:924-31.
11. Anthoney DA, Mcllwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug resistant tumor cells. Cancer Res 1996;56:1374-81.
12. Moreland NJ, Illand M, Kim YT, Paul J, Brown R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 1999;59:2102-6.
13. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60:6039-44.
14. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
15. Rustin GJS, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 1996;14:1545-51.
16. Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5.
17. Strathdee G, Appleton K, Illand M, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001;158:1121-7.
18. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
19. Vasey PA. Survival and longer-term toxicity results of the SCO-TROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:804.
20. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective tumor cell lines. Cancer Res 1997;57:808-11.
21. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001;85:1064-9.
22. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
23. De Wind N, Dekker M, van Rossum A, et al. Mouse models for hereditary nonpolyposis colorectal cancer Cancer Res 1998;58: 248-55.
24. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
25. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-7.
26. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998;22:1449-62.
27. Tammela J, Geisler JP, Eskew PN Jr, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998;19:438-40.
28. Samimi G, Fink D, Varki NM, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000;6:1415-21.
29. Mackay HJ, Cameron D, Rawhilly M, et al. Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival. J Clin Oncol 2000;18:87-93.
30. Duckett DR, Bronstein SM, Taya Y, Modrich P. hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci USA 1999;96:12384-8.
31. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003;100:2420-5.
32. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003;39:2142-9.
33. Wei SH, Chen C-M, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002;8:2246-52.